Clinical Trial Update: Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) [Phase 2]

View source ↗

Summary

Phase 2 STROBE trial evaluating HRD-driven benefit from combining olaparib with bevacizumab in ovarian cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Lynparza (olaparib)

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: Ovarian Cancer | Phase 2 | Status: RECRUITING